CelLBxHealth PLC (CLBX)

Industry Diagnostics & Research

This stock can be held in an Investment ISA, SIPP and Investment Account

Sell

1.70p

Buy

1.85p

arrow-up0.00p (+0.00%)

Prices updated at 12 Jun 2026, 16:32 BST

Prices minimum 15 mins delay

Prices in GBX

CelLBxHealth PLC is active in the healthcare sector in the United Kingdom. The Company's principal trading activity is undertaken in relation to the development and commercialization of the Parsortix cell separation system, with deployment in liquid b ...

FTSE All-Share

1.61%

LSE

Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and

our Investment Fees and Charges.

Sector

Healthcare

Industry

Diagnostics & Research

Chairman

Dr. Jan Groen

CEO

Mr. Peter Collins

Most recent earnings

31 Dec 2024

Fiscal year end

31 Dec 2024

Employees

119

Head office

10 Nugent Road

Guildford

United Kingdom

GU2 7AF

+44 1483343434

investor@angleplc.com

Company website

Key personnel

Owner name chevron-l-regular chevron-r-regular	Salary
Mr. Brian Howlett Non-Executive Director, Senior Independent Director	-
Dr. Jan Groen Non-Executive Director, Chairman	-
Mr. Peter Collins Executive Director, Chief Executive Officer	-

Top 5 shareholders

Owner name chevron-l-regular chevron-r-regular	No. of shares
Unicorn Asset Management Ltd	2,769,230
Unicorn AIM VCT Series 3 ORD	2,769,230
Zeus Investment Management Limited	2,500,000
SVS Zeus Dynamic Opportunities Fund	2,500,000
Hargreave Hale Limited	1,871,174

Director dealings

Date chevron-l-regular chevron-r-regular	Action
15 Dec 2025	Purchase
15 Dec 2025	Purchase

Please note that past performance is not a reliable indicator of future returns.

Important Information

Investment values, and income from investments, can go down as well as up, so you may get back less than you invest. This is not a personal recommendation for a specific investment. If you're not sure which investments are suitable for you, consult Fidelity's advisers or another authorised financial adviser. The information contained herein: is proprietary to Morningstar and/or its content providers; may not be copied or distributed; and is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.